Drug Profile
Insulin glargine biosimilar - Samsung Bioepis
Alternative Names: Lusduna; LUSDUNA Nexvue; MK 1293; SB 9Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Samsung Bioepis
- Developer Merck & Co; Samsung Bioepis
- Class Antihyperglycaemics; Insulins; Pancreatic hormones
- Mechanism of Action Insulin receptor agonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Diabetes mellitus
- Phase III Type 1 diabetes mellitus; Type 2 diabetes mellitus